中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2012年
5期
377-380
,共4页
郑朝旭%冯强%徐泉%谢玉权%梁建明%袁兴华
鄭朝旭%馮彊%徐泉%謝玉權%樑建明%袁興華
정조욱%풍강%서천%사옥권%량건명%원흥화
胃肿瘤%T淋巴细胞亚群%手术后并发症%疫苗
胃腫瘤%T淋巴細胞亞群%手術後併髮癥%疫苗
위종류%T림파세포아군%수술후병발증%역묘
Vaccines
目的 评价术中铜绿假单胞菌注射液腹腔置药对胃癌患者细胞免疫功能的影响及安全性.方法 将72例进展期胃癌患者随机分为铜绿假单胞菌腹腔置药组(实验组,41例)和对照组(31例).实验组术毕于瘤床放置铜绿假单胞菌注射液8～10ml.分别在术前、术后10、20、30 d采集两组患者的静脉血测定淋巴细胞总数、淋巴细胞亚群,观察患者围手术期并发症及药物不良反应.结果 实验组淋巴细胞总数[(1.77±0.58)×109/L]与对照组[(1.61±0.52)×109/L]比较明显提高,差异有统计学意义(P=0.042)；实验组CD3+细胞(76.36±9.47)与对照组(68.63±10.34)比较明显提高,差异有统计学意义(P=0.027)；实验组NK细胞(14.92±8.65)与对照组(14.61±10.31)比较明显提高(P=0.012),差异有统计学意义(P=0.027)；实验组CD8+细胞(30.89±9.89)与对照组(30.53±9.26)比较明显下降,差异有统计学意义(P-0.037),而两组的CD4+细胞数和CD4+/CD8+相比差异无统计学意义(均P＞0.05).铜绿假单胞菌注射液对患者的血常规及肝、肾功能均无明显影响,实验组的1年生存率(94.9％)高于对照组(83.3％),两组相比差异有统计学意义(P=0.022).结论 铜绿假单胞菌注射液的腹腔给药方式安全可行,对进展期胃癌患者具有明显的免疫调节作用.
目的 評價術中銅綠假單胞菌註射液腹腔置藥對胃癌患者細胞免疫功能的影響及安全性.方法 將72例進展期胃癌患者隨機分為銅綠假單胞菌腹腔置藥組(實驗組,41例)和對照組(31例).實驗組術畢于瘤床放置銅綠假單胞菌註射液8～10ml.分彆在術前、術後10、20、30 d採集兩組患者的靜脈血測定淋巴細胞總數、淋巴細胞亞群,觀察患者圍手術期併髮癥及藥物不良反應.結果 實驗組淋巴細胞總數[(1.77±0.58)×109/L]與對照組[(1.61±0.52)×109/L]比較明顯提高,差異有統計學意義(P=0.042)；實驗組CD3+細胞(76.36±9.47)與對照組(68.63±10.34)比較明顯提高,差異有統計學意義(P=0.027)；實驗組NK細胞(14.92±8.65)與對照組(14.61±10.31)比較明顯提高(P=0.012),差異有統計學意義(P=0.027)；實驗組CD8+細胞(30.89±9.89)與對照組(30.53±9.26)比較明顯下降,差異有統計學意義(P-0.037),而兩組的CD4+細胞數和CD4+/CD8+相比差異無統計學意義(均P＞0.05).銅綠假單胞菌註射液對患者的血常規及肝、腎功能均無明顯影響,實驗組的1年生存率(94.9％)高于對照組(83.3％),兩組相比差異有統計學意義(P=0.022).結論 銅綠假單胞菌註射液的腹腔給藥方式安全可行,對進展期胃癌患者具有明顯的免疫調節作用.
목적 평개술중동록가단포균주사액복강치약대위암환자세포면역공능적영향급안전성.방법 장72례진전기위암환자수궤분위동록가단포균복강치약조(실험조,41례)화대조조(31례).실험조술필우류상방치동록가단포균주사액8～10ml.분별재술전、술후10、20、30 d채집량조환자적정맥혈측정림파세포총수、림파세포아군,관찰환자위수술기병발증급약물불량반응.결과 실험조림파세포총수[(1.77±0.58)×109/L]여대조조[(1.61±0.52)×109/L]비교명현제고,차이유통계학의의(P=0.042)；실험조CD3+세포(76.36±9.47)여대조조(68.63±10.34)비교명현제고,차이유통계학의의(P=0.027)；실험조NK세포(14.92±8.65)여대조조(14.61±10.31)비교명현제고(P=0.012),차이유통계학의의(P=0.027)；실험조CD8+세포(30.89±9.89)여대조조(30.53±9.26)비교명현하강,차이유통계학의의(P-0.037),이량조적CD4+세포수화CD4+/CD8+상비차이무통계학의의(균P＞0.05).동록가단포균주사액대환자적혈상규급간、신공능균무명현영향,실험조적1년생존솔(94.9％)고우대조조(83.3％),량조상비차이유통계학의의(P=0.022).결론 동록가단포균주사액적복강급약방식안전가행,대진전기위암환자구유명현적면역조절작용.
Objective To evaluate the safety and effects of pseudomonas aerug PA-MSHA vaccine on cytoimmunity in advanced gastric cancer patients. Methods Seventy two patients with advanced gastric cancer were randomly divided into experimental group and control group. Tumor bed was treated intraoperatively by pseudomonas vaccine injection in experimental group.The venous bloods were sampled prior to surgery (preoperative) and on days 10,20,and 30 postoperatively.The total lymphocyte count and lymphocyte subpopulations were detected while the postoperative complications and adverse drug reaction were observed,prognosis was evaluated. Results The total lymphocyte count(P =0.042) and the counts ofCD3+ lymphocyte(P =0.027) and NK cell increased (P =0.012) obviously in experimental group.CD8+ lymphocyte decreased(P =0.037),but the counts of CI4+ lymphocyte and CD4+/CD8+ were not significantly different.Complications were not significantly different in the two groups.One year survival rate was longer ( 94.9％ ) in experimental group than that in the control group ( 83.3％ ) ( P =0.022 ).Conclusions Peritoneal cavity administration with pseudomonas aerug vaccine was safe,and effectively helps regulate cytoimmunity in postoperative patients of advanced gastric carcinoma.
